Latest news

Thumbnail image for Lilly, Nektar to co-develop new immunotherapy

Lilly, Nektar to co-develop new immunotherapy

Eli Lilly and Nektar Therapeutics have signed a pact to co-develop the latter’s experimental immunotherapy NKTR-358 for a range of autoimmune and other chronic inflammatory conditions under a deal valued at $400 million.

25th July 2017

Thumbnail image for RCGP warns that GP access is set to worsen

RCGP warns that GP access is set to worsen

In just five years patients across England could be waiting more than a week for an appointment with a GP or practice nurse on more than 100 million occasions, according to a new projection by the Royal College of GPs.

25th July 2017

Thumbnail image for MSD’s Keytruda backed for bladder cancer

MSD’s Keytruda backed for bladder cancer

European regulators have backed expanding approval of MSD’s immunotherapy Keytruda to include the treatment of locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.

25th July 2017

Thumbnail image for ViiV’s long-acting two-drug HIV regimen hits targets

ViiV’s long-acting two-drug HIV regimen hits targets

A long-acting, two-drug HIV regimen being co-developed by ViiV Healthcare and Janssen Sciences Ireland UC has shown comparable viral suppression rates to a three-drug regimen in a Phase II trial, indicating its potential to reduce the dosing burden for patients and thus improve treatment adherence.

25th July 2017

Thumbnail image for GSK files for extended use of Relvar Ellipta in asthma

GSK files for extended use of Relvar Ellipta in asthma

GlaxoSmithKline and Innoviva have applied to market Relvar Ellipta for extended use in patients with asthma who are already adequately controlled on inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy.

24th July 2017

Thumbnail image for Eleven medicines leap closer to EU approval

Eleven medicines leap closer to EU approval

Eleven therapies, including five targeting rare diseases, have taken a giant leap towards being approved in Europe after winning backing from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

24th July 2017

Thumbnail image for NICE u-turn backs use of Teva’s asthma biologic

NICE u-turn backs use of Teva’s asthma biologic

The National Institute for Health and Care Excellence (NICE) is now backing routine NHS commissioning of Teva’s Cinqaero to treat a severe form of asthma after having initially been minded to block the drug’s use.

21st July 2017

Thumbnail image for EU nod for Vifor’s Veltassa

EU nod for Vifor’s Veltassa

European regulators have approved Vifor Pharma’s new potassium binder Veltassa to treat hyperkalaemia in adult patients.

21st July 2017

Thumbnail image for Do you love your team?

Do you love your team?

If the answer is yes, take the first step toward getting your hands on the coveted Pharma by entering your Commercial Cross Functional Team into Marketer of the Year, today!

21st July 2017

Thumbnail image for EU approves LEO Pharma’s psoriasis biologic

EU approves LEO Pharma’s psoriasis biologic

A new treatment option has been approved in the European Union for patients with psoriasis, paving the way for access to a novel approach for those with moderate-to-severe forms of the disease who are candidates for systemic therapy.

20th July 2017

Thumbnail image for Final NHS green light for Amgen’s Kyprolis

Final NHS green light for Amgen’s Kyprolis

Patients living with multiple myeloma across England and Wales should now get ‘routine’ access to Amgen’s Kyprolis on the NHS within three months following a final green light from the National Institute for Health and Care Excellence.

20th July 2017

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download